Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
undruggable targets
Biotech
Argenx's $1.5B pact to turn macrocyclic peptides to new targets
Argenx wants to get in on the macrocyclic peptide action, penning a deal worth $1.5 billion in biobucks with Unnatural Products.
James Waldron
Jul 1, 2025 8:00am
GPCR firm Septerna files for IPO on strength of preclinical data
Oct 3, 2024 6:00am
AACR: KRAS inhibitors pop in preclinical data debuts
Apr 11, 2024 4:30am
Lilly inks backloaded $660M Prism drug discovery pact
Nov 29, 2023 5:53am
Roche pays $50M to Monte Rosa in latest molecular glue deal
Oct 17, 2023 8:25am
Sanofi pays $125M, offers up to $1.2B biobucks for Recludix deal
Jul 20, 2023 8:00am
